Shakespeare called King Richard III a hunchback, but new genetic and reconstructive CT data show this story had more of a twist. Until recently, the exact nature and whereabouts of Richard's physical deformity was a mystery. While questions still daunt researchers, a compelling picture of the monarch's spine has emerged.

In this video, BBC reporter Fergus Walsh is the first to undergo an MRI scan as part of the largest scan study to date and describes how the study is evolving.

IBA Molecular North America, Inc. (IBA Molecular) announced the signing of a 3-year group purchasing agreement with Premier, Inc. (Premier), a leading health care improvement company, to offer PET radiopharmaceuticals, including 18F-Fluorodeoxyglucose (FDG), a diagnostic radiotracer used in oncology, neurology and cardiology, to Premier member imaging centers across the country.

Watch a fly-through of Glass Brain, a 3D imagining of the human brain by researchers at the University of California San Francisco. This video shows the 3D brain model made possible by electroencephalography data and white matter tract reconstruction from MRI diffusion tensor imaging. UCSF is using the technology to research possible treatments for neurodegenerative disease.

The human genome was first mapped just a little over a decade ago. Its 3 billion bits of DNA are the pages of the human instruction manual. Read this great review featuring Eric S. Lander from MIT, Harvard, and the Broad Institute in Cambridge to see how far we've come and what the future of genomics holds.

The shape of cancer genomics may be a new calling card for 3D oncologic imaging. Studying the formation of cancer cell genomes could potentially provide more information about a patient's cancer than just focusing on genetic expression. Scientists at McGill University in Montreal are finding that the form of a cancer cell genome can even tell them what subtype of cancer a patient has.

Biopharmaceutical giant Bristol-Myers Squibb now holds the power on a pipeline of neurodegenerative disease therapies after buying San Francisco-based iPierian for $175 million.

Advanced gene sequencing has found a single genetic mutation essential for a brain disorder that has been plaguing Turkish families for centuries.